Combining JAK2 inhibitors with BCL-2 inhibitors such as venetoclax could synergistically enhance leukemia cell death by both disrupting survival signaling (via JAK2 inhibition) and promoting apoptosis (via BCL-2 inhibition). This evidence concerns the gene JAK2 and leukemia.